EUVIMEDEUVIMED entdecken
Crossref

AB036. Effect of neoadjuvant and adjuvant chemotherapy in patients with thymic epithelial tumours

Eirini Konstantinidou, Eleni Josephides, Diluxshan Sritharan, Mariam Jallow, Shahreen Ahmad, Daniel Smith, Michael Skwarski, Daniel Hughes, Sharmistha Ghosh, Spyridon Gennatas, Alexandros Georgiou, Mieke Van Hemelrijck und 12 weitere

Mediastinum · 2026-10 · 10 · AB036-AB036

DOI: 10.21037/med-26-ab036 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Mediastinum, 2026-10. Verfasst von Eirini Konstantinidou und 23 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Thymic epithelial tumours (TETs) are rare malignancies for which surgical resection is the primary curative treatment. Chemotherapy may be given neoadjuvantly to facilitate resection of locally advanced disease, or adjuvantly to reduce recurrence risk, but the impact of these strategies is not well defined. METHODS: We retrospectively reviewed demographic, disease, treatment and outcome data for all patients with histologically confirmed TETs managed at our centre (April 2011–November 2022). Disease was staged per tumor-node-metastasis (TNM) 8th edition. Survival outcomes were analysed using Kaplan-Meier and log-rank tests. RESULTS: 206 patients were identified (52% male; median age 63 years); 189 (92%) had thymoma, 16 (8%) thymic carcinoma and 1 thymic atypical carcinoid. Thirty-six patients (17.5%) received neoadjuvant chemotherapy (NACT), given only for stage II–IV disease (30 thymoma, 6 thymic carcinoma), and were compared with 14 stage II–IV patients managed without NACT (10 thymoma, 3 thymic carcinoma and 1 atypical carcinoid). NACT patients had more advanced disease than patients without NACT (Stage III/IV 94.4% vs. 57.1%, P=0.003). All NACT patients proceeded to surgery; R0 resection was achieved in 58.3% of patients (Stage II 100%, Stage III 64.7%, Stage IV 47.1%), and pathologic complete response (pCR) in 11.1% (all thymoma). Recurrence was numerically higher with NACT than without (38.9% vs. 14.3%, P=0.18), 5-year event free survival (EFS) was 46.5% vs. 60.9% (P=0.79), and 5-year overall survival (OS) was 80.9% vs. 66.6% (P=0.47). Thirteen patients (6.3% of total; 11 thymoma, 2 thymic carcinoma) received adjuvant chemotherapy, more often for higher-stage disease (P

Zitieren

APA

Konstantinidou, E., Josephides, E., Sritharan, D., Jallow, M., Ahmad, S., Smith, D., Skwarski, M., Hughes, D., Ghosh, S., Gennatas, S., Georgiou, A., Hemelrijck, M. V., Syrigos, N., Colvin, M., McDowall, E., Harrison-Phipps, K., Ashrafian, L., Routledge, T., Tan, C., …, & Karapanagiotou, E. (2026). AB036. Effect of neoadjuvant and adjuvant chemotherapy in patients with thymic epithelial tumours. Mediastinum, 10, AB036-AB036. https://doi.org/10.21037/med-26-ab036

Vancouver

Konstantinidou E, Josephides E, Sritharan D, Jallow M, Ahmad S, Smith D, et al. AB036. Effect of neoadjuvant and adjuvant chemotherapy in patients with thymic epithelial tumours. Mediastinum. 2026;10:AB036-AB036. doi:10.21037/med-26-ab036

BibTeX
@article{Konstantinidou2026,
  author = {Konstantinidou, Eirini and Josephides, Eleni and Sritharan, Diluxshan and Jallow, Mariam and Ahmad, Shahreen and Smith, Daniel and Skwarski, Michael and Hughes, Daniel and Ghosh, Sharmistha and Gennatas, Spyridon and Georgiou, Alexandros and Hemelrijck, Mieke Van and Syrigos, Nikolaos and Colvin, Marrika and McDowall, Ellie and Harrison-Phipps, Karen and Ashrafian, Leanne and Routledge, Tom and Tan, Carol and Patel, Akshay and Santis, George and Young, Thomas and Bille, Andrea and Karapanagiotou, Eleni},
  title = {AB036. Effect of neoadjuvant and adjuvant chemotherapy in patients with thymic epithelial tumours},
  journal = {Mediastinum},
  year = {2026},
  volume = {10},
  pages = {AB036--AB036},
  doi = {10.21037/med-26-ab036}
}
Kostenlos starten →